Login to Your Account



Alnylam Scores Big on Its Phase I Data for ALN-TTRsc

By Marie Powers
Staff Writer

Thursday, July 11, 2013
Robust Phase I findings for ALN-TTRsc, a subcutaneously administered RNAi therapy targeting transthyretin (TTR) in TTR-mediated amyloidosis, propelled Alnylam Pharmaceuticals Inc. to a 52-week high Thursday morning.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription